Abstract: Data about Cystatin-C levels in HIV-infected patients with metabolic syndrome (MetS) are still limited. Therefore, the aim of this study was to evaluate the possible correlations of serum levels of Cystatin-C in HIV/AIDS patients treated with combined antiretroviral therapy (cART) with or without MetS. This cross-sectional study included 89 HIV/AIDS Caucasian patients receiving cART at the HIV/AIDS Centre Belgrade, Serbia, divided into two groups according to the presence of MetS. Cystatin-C and other biochemical parameters were measured using Cytokine-Array-I, Metabolic-Array-I and Metabolic-Array-II, at the
even nowadays, data about the levels of Cystatin C in HIV-infected patients with MetS are still limited.
The aim of this study was to evaluate the possible correlations of serum levels of Cystatin C and the presence of MetS in HIV/AIDS patients treated with cART.
Methods
Patients. Eighty-nine adult HIV/AIDS patients, all Caucasians, receiving cART for at least 6 months, participated in this crosssectional study. They were recruited from June 2012 to January 2013 at the HIV/AIDS Centre of the University Teaching Hospital for Infectious and Tropical Diseases in Belgrade, Serbia.
The main inclusion criteria were as follows: age of 18 years and older, confirmed diagnosis of HIV infection (stages A-C according to the 1993 Centers for Disease Control case definition criteria) [20] . Exclusion criteria were as follows: acute and chronic inflammatory diseases, malignancy, oedema syndrome or ascites and rare metabolic disorders such as Morbus Wilson and haemochromatosis, rapid weight loss, chronic alcohol/drug usage, and pregnancy or breastfeeding. To minimize the effect of renal dysfunction on Cystatin C levels, subjects with prevalent mild/severe renal dysfunction (glomerular filtration rate <60 mL/min/1.73 m 2 ) were excluded.
This study was conducted in accordance with the guidelines proposed in the Declaration of Helsinki. All patients gave informed consent, and the study was approved by the Ethics Committee of the School of Medicine, University of Belgrade.
For each patient, the following information was collected: demographic data (age, gender, medical history and physical findings, routes of HIV infection, duration of cART (months), number of Author for correspondence: Gordana Dragovi c, Department of Pharmacology, Clinical Pharmacology and Toxicology, School of Medicine, University of Belgrade, Dr Subotica 1, 11129 Belgrade, Serbia (e-mail gozza@beotel.net).
antiretroviral (ARV) combinations, and CD4
+ T cell counts. The patients were interviewed and clinically examined. Blood pressure was measured in the sitting position using a mercury sphygmomanometer according to the guidelines [21] . Weight (kg) and height (m) were measured, as well as the waist circumference (cm). Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in metres.
Subjects were classified into two groups, HIV/AIDS patients with MetS and HIV/AIDS patients without MetS. HIV/AIDS patients with MetS had at least three of the following five criteria: waist circumference over 94 cm for males and 80 cm for females, increased blood pressure (systolic ≥130 mmHg and/or diastolic ≥85 mmHg), elevated triglycerides (≥1.7 mmol/L), reduced high-density lipoprotein (HDL) cholesterol (<1.03 mmol/L in males and <1.29 mmol/L in female subjects) and elevated fasting glucose (≥ 5.6 mmol/L) [22] . Patients with less than three of five of these components of MetS were considered as patients without MetS.
Biochemical analysis. Individual blood samples were collected in the morning after an overnight fasting period of at least 12 hr. Measurement of total cholesterol, HDL cholesterol, low-density lipoprotein cholesterol, triglycerides, fasting insulin, fasting plasma glucose, liver transaminases [alanine transaminase (ALT), aspartate transaminase (AST)] and alkaline phosphatase (ALP) were taken using an automatic analyser (Acusera Riqas, Randox Laboratories Ltd., London, UK).
Cystatin-C and C-reactive protein were measured using the Metabolic Syndrome Array II (Randox Laboratories Ltd.), and TNF-a was measured using Cytokine Array I (Randox Laboratories Ltd.), while plasminogen activator inhibitor-1 (PAI-1), and insulin levels were measured using the Metabolic Syndrome Array I (Randox Laboratories Ltd.). All biochemical analyses were performed at the Department of Clinical Biochemistry, Royal Free Hospital and University College London, UK.
Patients were also tested for hepatitis C virus (HCV) antibody, hepatitis B surface antigen and antibody, HBe antigen and antibody (HBV) using commercial ELISA assays.
Insulin resistance was determined using the homeostasis model assessment index (HOMA-IR), calculated as a product of the fasting plasma insulin level (mIU/L) and the fasting plasma glucose level (mmol/L) divided by 22.5 [23] .
Virologic and immunological markers. CD4 + T cell counts were obtained by cytofluorimetric assessment of lymphocyte subpopulations. HIV-RNA plasma viral load (pVL) was determined using a quantitative reverse transcriptase polymerase chain reaction (ultrasensitive assay version 1.5 Roche Molecular Systems, Branchburg, NJ, USA) with detection limit ˃50 HIV RNA copies/mL plasma (1.7 log 10 ).
Statistical
analysis. Data are presented as count (%), mean AE standard deviation (S.D.) or median (25th-75th percentile), depending on data type. Groups were compared using independent samples t-test for normal distributed data and Mann-Whitney U test for non-normal distributed data. Pearson correlation analysis was used to assess correlation between continuous variables. A linear regression model was performed to evaluate which clinical and laboratory variables had an independent effect on Cystatin C levels in HIV/AIDS patients. Cystatin C levels were the dependent outcome, and gender, CRP, ALP and MetS were included as either continuous or dichotomous data. Variables with non-normal data had to be transformed. Best results were obtained by logarithmic-transformation.
Variables that were not significant (p ≥ 0.05) were excluded from the analysis. All statistical analysis was performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA).
Results
The study group consisted of 89 HIV-infected patients, 69 (78%) males and 20 (22%) females. According to CDC classification, 46 patients (52%) had AIDS. Among the study patients, the predominant group was the men-having-sex-withmen (MSM) population, with 46 (52%) patients. Thirty-four (38%) patients had acquired HIV infection via heterosexual contact, three (3%) via transfusion of blood and blood products and one (1%) via vertical transmission. Four (5%) patients were intravenous drug users, and in one patient (1%), transmission risk group remained unknown. Ten (11%) patients had HBV co-infection while five (5%) had HCV coinfection. Forty-three HIV/AIDS patients were current smokers. All patients had undetectable HIV RNA plasma viral load and relatively good immunological status. Baseline characteristics of all patients are presented in table 1.
Thirty-three (37%) subjects presented three or more criteria for MetS. There were 56 (63%) patients without MetS. Patients with or without MetS did not show significant differences in age, and they were homogenous for duration of ARV therapy (in months), number of ARV combinations and CD4 + T cell count. However, the group of patients with MetS showed statistically higher levels of anthropometric parameters such as BMI (p < 0.001) and waist circumference (p < 0.001), when compared with the group of patients without MetS (table 1) . Patients with MetS presented statistically higher levels of aspartate transaminase (AST) (p = 0.024) and triglycerides (p = 0.001) and statistically lower level of HDL (p = 0.001). Furthermore, systolic blood pressure (p < 0.001), diastolic blood pressure (p < 0.001), fasting glucose (p < 0.001) and HOMA-IR were statistically increased in the group of patients with MetS, when compared with patients without MetS. All clinical and biochemical characteristics describing patient groups are presented in table 2. Among CVD, carotid artery disease (p = 0.017) and hypertension (p < 0.001) were To evaluate which clinical and laboratory variables were correlated with serum levels of Cystatin C levels in HIV/AIDS patients, we showed a positive correlation of Cystatin C and alkaline phosphatase (ALP) (r = 0.224, p = 0.036) and C-reactive protein (CRP)
Discussion
Metabolic syndrome has high prevalence worldwide, affecting almost a quarter of the world's adult population [22] .
Increasing survival of HIV/AIDS patients receiving cART makes these patients particularly prone to MetS [24] . Previous studies have shown higher levels of Cystatin C in patients with the MetS in the general population, independently of renal function [13, 14] . However, data about Cystatin C in HIV-infected patients with MetS are still limited.
We conducted a cross-sectional study to evaluate whether the serum levels of Cystatin C were correlated with the presence of MetS in HIV/AIDS patients treated with cART. Our study population was similar to the population of HIV patients in Western European countries with MSM and heterosexual patients as predominant groups [25] , as well as the prevalence of MetS in HIV/AIDS patients [24, 26, 27] .
In our study, we also analysed whether longer duration of cART and greater number of antiretroviral combinations were associated with MetS. However, there were no differences between the group of HIV/AIDS patients with MetS and the group without MetS regarding duration of cART and number of antiretroviral combinations. Literature data about effect of cART on prevalence of MetS are still inconsistent. While Santiprabhob et al. [28] suggest that longer duration of cART is associated with MetS, Tiozzo et al. [29] report that Mets is a more disease-dependent or lifestyle-dependent constellation of symptoms in people living with HIV. Furthermore, de Waal et al. [30] reported that central fat gain did not seem to be an antiretroviral adverse drug reaction. However, they suggest that central fat gain could be a consequence of treating HIV infection, through decreasing of inflammatory markers such as TNF a that are known to cause wasting.
In our study, HIV/AIDS patients with MetS showed statistically higher levels of anthropometric parameters such as BMI, Results are presented as mean AE standard deviation (S.D.) or n (%). MetS, metabolic syndrome; AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase; HDL, high-density lipoprotein; LDL, low-density protein; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment of insulin resistance; TNF-a, tumour necrosis factor alpha; CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor-1. and the waist circumference, as well as systolic and diastolic blood pressure, triglycerides, fasting glucose and HOMA-IR, and lower levels of HDL, when compared with the group of patients without MetS. Most of these parameters are criteria for MetS and are in accord with the evidence existing in the literature [24, [26] [27] [28] [29] . Furthermore, HIV/AIDS patients with MetS showed higher AST levels, when compared with patients without MetS. Similar results were reported by Sterling et al. [31] and Lombardi et al. [32] . Significant liver disease may develop in HIV mono-infected patients, usually associated with fatty liver and/or cART exposure [33] . However, other potential factors, such as concomitant diseases (HBV and HCV infections) or therapies, can confound these results and decrease the ability to adequately interpret findings on the relationships between HIV, AST levels and MetS. Finally, the most interesting finding of the present study concerns elevated levels of Cystatin C in HIV/AIDS patients with MetS. Similar results were found in the general population [13] [14] [15] [16] [17] 34] , but data about Cystatin C in HIV/AIDS patients with MetS are still limited. However, it should be stressed that, according to our knowledge, this is the first study with elevated Cystatin C levels in patients with MetS, in a HIV-positive cohort. Previous studies showed elevated levels of Cystatin C in HIV/AIDS patients, when compared to the general population [11] . Recently, Liu et al. [14] showed that Cystatin C has been associated with insulin resistance, components of MetS and inflammation. Maahs et al. [35] also suggested a complex relationship which exists among Cystatin C, BMI and progression of CVD. In contrast to previous studies, Kim et al. [36] reported no association between serum Cystatin C level and CVD in diabetic patients. However, these authors did not evaluate the relationship between Cystatin C levels and other inflammatory markers, BMI or other variables.
In the present study, similar to prior studies, we showed a positive correlation of Cystatin C and ALP, and C-reactive protein, in HIV/AIDS patients [12, 37, 38] . In patients with HIV infection, there is increasing evidence that a persistent inflammatory state is responsible for the early development of metabolic complications [39] . CRP is a marker of systemic low-grade inflammation, and it has been suggested as biomarker of CVD risk among HIV-positive individuals [40] . The factors driving this persistent immune activation, particularly during effective treatment, are poorly understood. Sanders et al., on the other hand, suggested that inflammation and cytokine expression can also vary as HIV infection progresses through the chronic phase of disease [41] .
Using linear regression modelling, we obtained significant correlations between Cystatin C and other variables significant in univariate analysis. MetS is significant and parameter with highest standardized coefficient in analysis. Similar, CRP and ALP revealed significant correlation with Cystatin C independently of MetS and each other. It should be stressed that literature data suggest numerous factors associated with elevated Cystatin C levels in HIV-infected individuals such as hepatitis C co-infection, hypertension, current smoking, older age, detectable HIV-RNA pVL and elevated microalbuminuria [42] . Our results showed strong association of Cystatin C levels with CRP, ALP and MetS, in HIV/ AIDS patients. However, we excluded HIV/AIDS patients with chronic renal disease and tried to evaluate the possible correlations of serum levels of Cystatin C and the presence of MetS in HIV/AIDS patients treated with cART. Nevertheless, routine measurement of Cystatin C in HIV/AIDS patients is still impossible due to high cost. Therefore, further respective research studies are necessary to better evaluate the association between Cystatin C and MetS in HIV/ AIDS patients.
There were several strengths of our study. Firstly, our study is one of the first to examine the association of Cystatin C and MetS, in HIV/AIDS patients. Secondly, we had a more robust sample size compared to a prior similar study with Cystatin C in HIV/AIDS patients [38] . Additionally, we also examined a significantly greater number of clinical, laboratory and anthropometric/body measurements, as well as cART duration and number of ARV combinations.
Limitations of this study include the relatively small sample size and the heterogenous therapy consisting of a wide range of treatment duration and various ARV combinations with older antiretroviral drugs, which are currently still used in Serbia [43] .
Conclusions
Our study showed, for the first time, elevated Cystatin C levels in HIV/AIDS patients with MetS. As HIV/AIDS patients appear to be at high risk of CVD, early assessment of MetS using novel markers, such as Cystatin C, may ultimately help increase the lifespan of these patients. Dependent variable: tCYSC, log-transformed Cystatin C; statistic F = 6.792, p < 0.001 and R 2 = 0,249; tCRP, log-transformed C-reactive protein; ALP, alkaline phosphatase; MetS, metabolic syndrome.
